QUÉBEC CITY, Oct. 10, 2012
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced that George R. Merriam, MD, Director of the Clinical
Study Unit at the VA Puget Sound Health Care System, and Professor
of Medicine at the University of Washington,
Seattle and Tacoma, WA,
will give an oral presentation on AEZS-130, Aeterna Zentaris'
ghrelin agonist, at the 6th International Congress of
the Growth Hormone Research (GRS) and Insulin-like Growth Factor
(IGF) Society, which will be held in Munich, Germany, October 17-20, 2012.
The presentation titled, "Use of an orally-active ghrelin
mimetic, macimorelin (AEZS-130), as a safe, simple test for Adult
Growth Hormone Deficiency (AGHD): Effect of BMI on optimal cut
off ", will take place on Thursday,
October 18, 2012, from 4:30 to 4:45
pm (local time), in the Black Box Room of the Gasteig
Conference Center.
About AEZS-130
AEZS-130, a ghrelin agonist, is a novel orally-active small
molecule that stimulates the secretion of growth hormone. The
Company has completed a Phase 3 trial for use as an oral diagnostic
test for AGHD. AEZS-130 has been granted orphan drug designation by
the FDA for use in this indication. Aeterna Zentaris owns the
worldwide rights to AEZS-130.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. The Company's pipeline encompasses compounds
at all stages of development, from drug discovery through to
marketed products. For more information please visit
www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.